133 related articles for article (PubMed ID: 23303227)
21. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.
Hosonuma K; Sato K; Yamazaki Y; Yanagisawa M; Hashizume H; Horiguchi N; Kakizaki S; Kusano M; Yamada M
Am J Gastroenterol; 2015 Mar; 110(3):423-31. PubMed ID: 25732417
[TBL] [Abstract][Full Text] [Related]
22. No more pilots, a phase III trial of fibrates in primary biliary cirrhosis is long overdue!
Halliday JS; Chapman RW
J Gastroenterol Hepatol; 2011 Sep; 26(9):1345-6. PubMed ID: 21884243
[No Abstract] [Full Text] [Related]
23. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
[TBL] [Abstract][Full Text] [Related]
24. New weapon for primary biliary cirrhosis from Japan.
Zeniya M
J Gastroenterol; 2003; 38(6):619-20. PubMed ID: 12858848
[No Abstract] [Full Text] [Related]
25. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group.
Poupon RE; Huet PM; Poupon R; Bonnand AM; Nhieu JT; Zafrani ES
Hepatology; 1996 Nov; 24(5):1098-103. PubMed ID: 8903382
[TBL] [Abstract][Full Text] [Related]
26. [Treatment of primary biliary cirrhosis with ursodeoxycholic acid].
Nikolovska D; Vasilev P; Mikhova A
Vutr Boles; 2000; 32(1):25-7. PubMed ID: 11195193
[TBL] [Abstract][Full Text] [Related]
27. Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis.
Almasio PL; Floreani A; Chiaramonte M; Provenzano G; Battezzati P; Crosignani A; Podda M; Todros L; Rosina F; Saccoccio G; Manenti F; Ballardini G; Bianchi FP; Scheuer PJ; Davies SE; Craxì A
Aliment Pharmacol Ther; 2000 Dec; 14(12):1645-52. PubMed ID: 11121914
[TBL] [Abstract][Full Text] [Related]
28. Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
Walker LJ; Newton J; Jones DE; Bassendine MF
Hepatology; 2009 Jan; 49(1):337-8; author reply 338. PubMed ID: 19035342
[No Abstract] [Full Text] [Related]
29. [Modern treatment of primary biliary cholangitis].
Strassburg CP
Internist (Berl); 2018 Jan; 59(1):105-112. PubMed ID: 29110023
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of colchicine in patients with primary biliary cirrhosis poorly responsive to ursodiol and methotrexate.
Lee YM; Kaplan MM
Am J Gastroenterol; 2003 Jan; 98(1):205-8. PubMed ID: 12526960
[TBL] [Abstract][Full Text] [Related]
31. Ursodeoxycholic therapy in chronic liver disease: a meta-analysis in primary biliary cirrhosis and in chronic hepatitis.
Simko V; Michael S; Prego V
Am J Gastroenterol; 1994 Mar; 89(3):392-8. PubMed ID: 8122652
[TBL] [Abstract][Full Text] [Related]
32. Effect of bezafibrate in primary biliary cirrhosis: a pilot study.
Ohmoto K; Mitsui Y; Yamamoto S
Liver; 2001 Jun; 21(3):223-4. PubMed ID: 11422787
[No Abstract] [Full Text] [Related]
33. The UDCA dosage deficit: a fate shared with CDCA.
Roda E; Liva S; Ferrara F; Azzaroli F; Giovanelli S; Nigro G; Festi D; Mazzella G
Eur J Gastroenterol Hepatol; 2002 Mar; 14(3):213-6. PubMed ID: 11953683
[TBL] [Abstract][Full Text] [Related]
34. Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study.
Eriksson LS; Olsson R; Glauman H; Prytz H; Befrits R; Rydén BO; Einarsson K; Lindgren S; Wallerstedt S; Wedén M
Scand J Gastroenterol; 1997 Feb; 32(2):179-86. PubMed ID: 9051880
[TBL] [Abstract][Full Text] [Related]
35. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.
Shi J; Wu C; Lin Y; Chen YX; Zhu L; Xie WF
Am J Gastroenterol; 2006 Jul; 101(7):1529-38. PubMed ID: 16863557
[TBL] [Abstract][Full Text] [Related]
36. Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid.
Boberg KM; Wisløff T; Kjøllesdal KS; Støvring H; Kristiansen IS
Aliment Pharmacol Ther; 2013 Oct; 38(7):794-803. PubMed ID: 23915021
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis.
Akbar SM; Furukawa S; Nakanishi S; Abe M; Horiike N; Onji M
J Gastroenterol; 2005 Feb; 40(2):157-63. PubMed ID: 15770399
[TBL] [Abstract][Full Text] [Related]
38. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study.
Lindor KD; Dickson ER; Jorgensen RA; Anderson ML; Wiesner RH; Gores GJ; Lange SM; Rossi SS; Hofmann AF; Baldus WP
Hepatology; 1995 Oct; 22(4 Pt 1):1158-62. PubMed ID: 7557866
[TBL] [Abstract][Full Text] [Related]
39. [Possibilities in the treatment of primary biliary cirrhosis].
Lengyel G; Tulassay Z
Orv Hetil; 2005 Jun; 146(23):1245-9. PubMed ID: 15988919
[TBL] [Abstract][Full Text] [Related]
40. Case of primary biliary cirrhosis-autoimmune hepatitis overlap which manifested after delivery.
Monoe K; Takahashi A; Katsushima F; Kanno Y; Saito H; Abe K; Yokokawa J; Ohira H
Intern Med; 2011; 50(12):1299-301. PubMed ID: 21673465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
